Literature DB >> 9080596

Immunoreactivity of a new generation of horse F(ab')2 preparations against European viper venoms and the tetanus toxin.

S Pépin-Covatta1, C Lutsch, M Grandgeorge, J M Scherrmann.   

Abstract

The immunoreactivity of the current and the new more purified, pasteurized preparations of horse F(ab')2 against the tetanus toxin and Vipera aspis venom was investigated with a biosensor based on technology using the optical phenomenon of surface plasmon resonance. Immunoreactivity data were compared with seroneutralization titres to investigate immunoreactivity-immunoprotection efficacy relationships. The association-dissociation rate and affinity constants of the current and the new tetanus toxin-specific F(ab')2 preparations were similar, at about 10(4) M-1 sec-1, 10(-4) sec-1 and 10(8) M-1, respectively. Similar values were found using a solid immunoradiometric assay. To assess the immunoreactivity of V. aspis venom-specific horse F(ab')2, the mol. wt and percentage of the antigenic fractions of V. aspis venom were determined. Western blotting of electrophoresis gels showed four antigenic fractions of V. aspis venom (mol. wts 17,500, 28,500, 32,000 and 60,000), which represented 6, 3.4, 17.7 and 5% of total venom, respectively. Association and dissociation rate constants were in the same range as those of the tetanus toxin-F(ab')2 interactions for each of the four antigenic fractions. Seroneutralization of both tetanus toxin and V. aspis by the corresponding specific F(ab')2 showed that the LD50 mg-1 protein was 1.76-fold and 1.51-fold higher with the new than with the current preparations, respectively. These improvements in efficacy were in close agreement with the higher immunoreactive fraction ratios, which were 2-fold and 1.8-fold higher with the new preparations. These results demonstrate that the removal of non-IgGT immunoglobulins and the pasteurization treatment have no overall influence on F(ab')2 affinity but improve the specific activity of these new antitoxin horse F(ab')2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9080596     DOI: 10.1016/s0041-0101(96)00144-4

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  2 in total

1.  Potent Neutralizing Activity of Polyclonal Equine Antibodies against SARS-CoV-2 Variants of Concern.

Authors:  Joanna Luczkowiak; Pauline Radreau; Ludovic Nguyen; Nuria Labiod; Fátima Lasala; Francisco Veas; Cécile Hélène Herbreteau; Rafael Delgado
Journal:  J Infect Dis       Date:  2022-08-03       Impact factor: 7.759

Review 2.  Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.

Authors:  Rashmi Dixit; Jenny Herz; Richard Dalton; Robert Booy
Journal:  Vaccine       Date:  2016-01-20       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.